IL6 and melanoma: Our data demonstrated that AR42 reduced gp130 levels by ∼40% and those of IL-6RA by ∼80% which collectively argues that overall IL-6 paracrine/autocrine signaling may be reduced in AR42 treated melanoma tumors.